lilly retatrutide trial Eli just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Lilly's triple agonist delivers up

[DOI] [PubMed] [Google Scholar] 53.Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

The manufacturer also offers a Home Delivery Program at $99/month or less with free shipping

They share the same ingredient and common side effects

Compared to popular GLP-1RAs like semaglutide, orforglipron does not require injection or an absorption enhancer with fasting to achieve exposure, and it can be taken without water or food restrictions, according to Phase 1 pharmacokinetic data

One AssuredPartners case study found GLP1 users saved about $560 per person per year in medical costs but against an average annual drug cost of $6,540, the nearterm ROI is negative for most employers

Novo Nordisk and Lilly are both filing for oral semaglutide and orforglipron